Zentalis Pharmaceuticals (ZNTL) Current Assets (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Current Assets of $218.1 million for Q1 2026, down 36.39% year-over-year from $342.9 million in Q1 2025, and down 13.86% quarter-over-quarter from $253.2 million in Q4 2025.
Zentalis Pharmaceuticals (ZNTL) Current Assets (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Current Assets history runs 8 years deep, the most recent figure standing at $218.1 million for Q1 2026.
- In Q1 2026, Current Assets fell 36.39% year-over-year to $218.1 million; the TTM figure through Mar 2026 stood at $218.1 million (down 36.39% YoY), while the FY2025 annual figure was $253.2 million, down 34.42% from the prior year.
- Current Assets for Q1 2026 stood at $218.1 million, down from $253.2 million in the prior quarter.
- The five-year high for Current Assets was $563.9 million in Q2 2023, with the low at $218.1 million in Q1 2026.
- The 5-year median for Current Assets is $410.2 million (2023), against an average of $399.9 million.
- The sharpest annual moves came in 2022 and 2026: Current Assets jumped 80.24% in 2022, then plunged 36.39% in 2026.
- Zentalis Pharmaceuticals' Current Assets stood at $451.9 million in 2022, then advanced by 9.91% to $496.7 million in 2023, then dropped by 22.28% to $386.1 million in 2024, then sank by 34.42% to $253.2 million in 2025, then fell by 13.86% to $218.1 million in 2026.
- Business Quant data shows ZNTL's Current Assets at $218.1 million in Q1 2026, $253.2 million in Q4 2025, and $288.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | 181.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 181.28 Mn |
| Mar 31, 2026 | 218.10 Mn |
| Dec 31, 2025 | 253.19 Mn |
| Sep 30, 2025 | 288.30 Mn |
| Jun 30, 2025 | 311.60 Mn |
| Mar 31, 2025 | 342.88 Mn |
| Dec 31, 2024 | 386.07 Mn |
| Sep 30, 2024 | 400.27 Mn |
| Jun 30, 2024 | 439.62 Mn |
| Mar 31, 2024 | 503.81 Mn |
| Dec 31, 2023 | 496.72 Mn |
| Sep 30, 2023 | 528.26 Mn |
| Jun 30, 2023 | 563.93 Mn |
| Mar 31, 2023 | 410.23 Mn |
| Dec 31, 2022 | 451.93 Mn |
| Sep 30, 2022 | 433.89 Mn |
| Jun 30, 2022 | 467.63 Mn |
| Mar 31, 2022 | 301.28 Mn |
| Dec 31, 2021 | 350.77 Mn |
| Sep 30, 2021 | 377.57 Mn |